Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Children with Osteogenesis Imperfecta
NCT02352753Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jun 2015
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of denosumab in osteogenesis imperfecta (OI), sponsored by Amgen. Primary endpoint: Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 months. Started Jun 2015; status: terminated.
02
Drugs
denosumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT02352753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352753.